Longevity: A Two-Part Single and Multiple Ascending Dose Trial of LBT-3627

Project: Longevity: A Two-Part Single and Multiple Ascending Dose Trial of LBT-3627

Trial Sponsor: Longevity Biotech

Clinical Trial Site: Alfred Hospital Movement Disorders Program

Project Summary:

With support from The Michael J. Fox Foundation for Parkinson’s Research, Longevity Biotech Australia is developing a new medication that’s focused on modulating the immune system. Researchers are investigating the safety and tolerability of LBT-3627. The trial will explore how this potential Parkinson’s medication acts in the body at different doses. This study has been approved by a Human Research Ethics Committee.